Artificial Intelligence (AI) in Oncology Market Size Analysis 2023 To 2032

The global artificial intelligence (AI) in oncology market size accounted for US$ 891.44 Mn in 2022 and is projected to reach around USD 10,680.29 Mn by 2032, growing at a CAGR of 28.18% from 2023 to 2032.

Artificial Intelligence (AI) in Oncology Market Size 2023 To 2032

Report Summary

The global artificial intelligence (AI) in oncology market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the artificial intelligence (AI) in oncology market across the globe.

A comprehensive estimate on the artificial intelligence (AI) in oncology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of artificial intelligence (AI) in oncology during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@https://www.precedenceresearch.com/sample/2638

Artificial Intelligence (AI) in Oncology Market Report Scope 

Report Coverage Details
Market Size in 2023 USD 1,142.72 Million
Market Size by 2032 USD 10,680.29 Million
Growth Rate from 2023 to 2032 CAGR of 28.18%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Component, By Cancer Type, By Treatment Type and By End-Users
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized artificial intelligence (AI) in oncology market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Immunohistochemistry Market Size To Cross USD 4.5 Bn By 2032

Artificial Intelligence (AI) in Oncology Market Players

The report includes the profiles of key artificial intelligence (AI) in oncology market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

Market Segmentation

By Component

By Cancer Type

By Treatment Type

By End-Users

Regional Segmentation

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Artificial Intelligence (AI) in Oncology Market 

5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Oncology Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Artificial Intelligence (AI) in Oncology Market, By Component

8.1. Artificial Intelligence (AI) in Oncology Market, by Component, 2023-2032

8.1.1. Software Solutions

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Hardware

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Services

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Artificial Intelligence (AI) in Oncology Market, By Cancer Type

9.1. Artificial Intelligence (AI) in Oncology Market, by Cancer Type, 2023-2032

9.1.1. Breast Cancer

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Lung Cancer

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Prostate Cancer

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Colorectal Cancer

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Brain Tumor

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Artificial Intelligence (AI) in Oncology Market, By Treatment Type 

10.1. Artificial Intelligence (AI) in Oncology Market, by Treatment Type, 2023-2032

10.1.1. Chemotherapy

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Radiotherapy

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Immunotherapy

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Artificial Intelligence (AI) in Oncology Market, By End-Users 

11.1. Artificial Intelligence (AI) in Oncology Market, by End-Users, 2023-2032

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Diagnostic Centers

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Pharmaceutical Companies

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Research Institutes

11.1.4.1. Market Revenue and Forecast (2020-2032)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Artificial Intelligence (AI) in Oncology Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.1.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.1.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.1.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.1.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.7.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.2.8.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.7.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.3.8.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.7.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.4.8.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.5.5.4. Market Revenue and Forecast, by End-Users (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)

12.5.6.4. Market Revenue and Forecast, by End-Users (2020-2032)

Chapter 13. Company Profiles

13.1. IBM

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Azra AI

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Siemens Healthineers

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. GE Healthcare

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Intel

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Path AI

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. NVIDIA

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Concert.AI

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Digital Diagnostics Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Median Technologies

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Exit mobile version